Key Info

Basic Information

Portrait: Prof. Dr. Rebekka Schneider-Kramann © Copyright: UKA
Prof. Dr. Rebekka Schneider-Kramann
Faculty / Institution:
Organizational Unit:
Division of Stem Cell Biology and Cellular Engineering
Excellent Science
Project duration:
01.05.2021 to 31.10.2022
EU contribution:
150.000 euros
  EU flag and ERC logo This project has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 966693)  


Novel Prognostic Personalized Biomarker and Therapeutic Target in Blood Cancer Related Fibrosis


The objective of this ERC Proof of Concept is to demonstrate the clinical application and commercial viability of a specific driver of the innate immune system as a novel predictive biomarker and as a novel therapeutic target for the diagnosis and treatment of bone marrow fibrosis related to blood cancer. This proposed project builds upon recent findings of my deFiber ERC Starting Grant (Stg) project, where we identified this danger-associated molecular pattern complex as exactly as such a prognostic and predictive biomarker and importantly showed that targeting with a small molecular, oral, anti-cancer inhibitor reduced fibrosis but also the cancer cell burden, in the sense of a targetable biomarker.

Additional Information

This grant is hosted at Erasmus Medical Center Rotterdam.